Viridian Therapeutics, Inc.
Clinical trials sponsored by Viridian Therapeutics, Inc., explained in plain language.
-
New hope for thyroid eye disease: phase 3 drug trial shows promise
Disease control OngoingThis study tests an investigational drug called VRDN-003 in 132 people with active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The goal is to see if the drug can reduce eye bulging by at least 2 millimeters compared to a placebo. Participant…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for chronic thyroid eye disease: phase 3 trial launched
Disease control OngoingThis study tests an investigational drug called VRDN-003 in 195 people with chronic thyroid eye disease, a condition that causes eye bulging and discomfort. The goal is to see if the drug can reduce eye bulging by at least 2 millimeters compared to a placebo. Participants receive…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New shot for bulging eyes moves to final testing phase
Disease control OngoingThis study tests an investigational drug called VRDN-003 for people with thyroid eye disease (TED). The main goal is to see if the drug is safe and how the body processes it. About 87 adults with TED will receive the drug as a shot under the skin. This is a Phase 3 trial, meaning…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control OngoingThis study tests an investigational drug called VRDN-003 in 321 adults with thyroid eye disease, a condition that can cause bulging eyes and discomfort. The main goal is to check the drug's safety and side effects over 24 weeks. Researchers will also measure if the drug helps red…
Phase: PHASE3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC